Get the Stockscreener App
3.77
1.34%
0.05
After Hours:
3.77
Neuphoria Therapeutics Inc stock is traded at $3.77, with a volume of 59,160.
It is up +1.34% in the last 24 hours and down -16.59% over the past month.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
See More
Previous Close:
$3.72
Open:
$3.65
24h Volume:
59,160
Relative Volume:
0.04
Market Cap:
$20.27M
Revenue:
$15.66M
Net Income/Loss:
$5.83M
P/E Ratio:
-0.1578
EPS:
-23.8939
Net Cash Flow:
$466.20K
1W Performance:
-3.58%
1M Performance:
-16.59%
6M Performance:
-46.14%
1Y Performance:
+0.00%
1-Day Range:
$3.645
$3.91
1-Week Range:
$3.645
$3.95
52-Week Range:
$2.90
$21.40
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
Name
Neuphoria Therapeutics Inc
Sector
Industry
Phone
781-439-5551
Address
100 SUMMIT DR, BURLINGTON
Compare NEUP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
3.77 | 20.00M | 15.66M | 5.83M | 466.20K | -23.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.78 | 117.45B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.50 | 82.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.82 | 52.92B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.45 | 52.02B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.34 | 37.94B | 447.02M | -1.18B | -906.14M | -6.1812 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-28-23 | Reiterated | Maxim Group | Buy |
| Jan-10-22 | Initiated | Berenberg | Buy |
| Jan-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-22 | Initiated | Evercore ISI | Outperform |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
View All
Neuphoria Therapeutics Inc Stock (NEUP) Latest News
Neuphoria Therapeutics Inc. (NEUP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Weekly Recap: Why Neuphoria Therapeutics Inc. stock could outperform in 2025Insider Buying & Free Fast Entry Momentum Trade Alerts - ulpravda.ru
What risks investors should watch in Neuphoria Therapeutics Inc. stockMarket Activity Recap & Fast Entry High Yield Stock Tips - Bölüm Sonu Canavarı
Published on: 2025-12-20 20:44:19 - Улправда
Published on: 2025-12-20 15:41:19 - Улправда
Why Neuphoria Therapeutics Inc. stock remains on watchlistsIPO Watch & Weekly Return Optimization Alerts - Улправда
How buybacks impact Neuphoria Therapeutics Inc. stock valueInsider Selling & AI Forecast Swing Trade Picks - Улправда
Will Neuphoria Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Chart Watch & Daily Entry Point Alerts - DonanımHaber
How Neuphoria Therapeutics Inc. stock reacts to global recession fears2025 Volume Leaders & AI Optimized Trade Strategies - Улправда
Is Neuphoria Therapeutics Inc. stock positioned for digital transformationWeekly Risk Summary & Weekly Stock Breakout Alerts - DonanımHaber
Does Neuphoria Therapeutics Inc. stock trade at a discount to peersWeekly Trend Summary & Smart Investment Allocation Insights - DonanımHaber
How Neuphoria Therapeutics Inc. stock benefits from global expansionJuly 2025 Drop Watch & Accurate Buy Signal Notifications - DonanımHaber
Neuphoria Therapeutics (NEUP) details 2025 annual meeting and vote outcomes - Stock Titan
Neuphoria Therapeutics (NASDAQ:NEUP) Cut to Strong Sell at Zacks Research - Defense World
Abeona Therapeutics (NASDAQ:ABEO) and Neuphoria Therapeutics (NASDAQ:NEUP) Critical Comparison - Defense World
ISS recommends shareholders vote for Neuphoria’s board nominees By Investing.com - Investing.com Australia
Leading Advisory Firms Recommend Voting FOR Lynx1's Independent Nominees - Yahoo Finance
Institutional Shareholder Services Recommends Shareholders of Neuphoria to Vote for its Director Nominees - marketscreener.com
ISS recommends shareholders vote for Neuphoria’s board nominees - Investing.com
Neuphoria Therapeutics (NEUP) Gains ISS Support for Director Nom - GuruFocus
Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees - The Manila Times
HC Wainwright Has Lowered Expectations for Neuphoria Therapeutics (NASDAQ:NEUP) Stock Price - Defense World
Analysts Are Bullish on Top Healthcare Stocks: Adicet Bio (ACET), Palvella Therapeutics (PVLA) - The Globe and Mail
Neuphoria Therapeutics (NEUP) Stock Analysis Report | Financials & Insights - Benzinga
HC Wainwright & Co. Maintains Neuphoria Therapeutics (NEUP) Buy Recommendation - Nasdaq
NEUP: Analyst Lowers Price Target by 66% but Maintains 'Buy' Rat - GuruFocus
Neuphoria continues strategic review amid reduced takeover offer By Investing.com - Investing.com Nigeria
Will Neuphoria Therapeutics Inc. stock deliver strong dividend growthIPO Watch & Weekly Watchlist for Hot Stocks - Newser
Neuphoria Therapeutics (NEUP) Considers Strategic Alternatives A - GuruFocus
Neuphoria continues strategic review amid reduced takeover offer - Investing.com
Neuphoria responds to Lynx1's revised indication of interest at a reduced price and premium - marketscreener.com
Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium - The Manila Times
Neuphoria (NASDAQ: NEUP) to Weigh Lynx1’s Reduced $4.75 Offer in Ongoing Review - Stock Titan
Is Neuphoria Therapeutics Inc. stock near bottom after declineEarnings Risk Report & Weekly Top Stock Performers List - Newser
Lynx1 Master Sends a Letter to the Shareholders of Neuphoria Therapeutics - marketscreener.com
Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders - Yahoo Finance
Lynx1 Master Fund Critiques Neuphoria Therapeutics Inc. Board's Capital-Raising Strategy and Proposes Independent Director Nominees in Proxy Statement - marketscreener.com
Neuphoria AFFIRM-1 trial misses primary endpoint, to discontinue SAD program - MSN
Neuphoria Therapeutics Inc Stock (NEUP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):